Viscosupplementation Market by Type (Single Injection, Three Injection, Five Injection), Age Group (Adults, Geriatrics), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), Application (Knee Osteoarthritis, Hip Osteoarthritis

Viscosupplementation Market by Type (Single Injection, Three Injection, Five Injection), Age Group (Adults, Geriatrics), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), Application (Knee Osteoarthritis, Hip Osteoarthritis, Hand Osteoarthritis, and Others), End Use (Hospitals, Orthopedic Clinics, and Others), and Region 2024-2032

The global viscosupplementation market size reached US$ 4.5 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 8.7 Billion by 2032, exhibiting a growth rate (CAGR) of 7.42% during 2024-2032. The increasing prevalence of osteoporosis and osteoarthritis (OA) and the shifting consumer inclination toward minimally invasive non-surgical treatments represent some of the key factors driving the market.

Viscosupplementation represents a minimally invasive medical procedure wherein intraarticular injection comprising gel-like fluid known as exogenous hydraulic acid (HA) derivatives are directly administered into the knee joints of the patient. It acts as a lubricant, which enables bones to move smoothly over each other, lowers inflammation, and performs as a shock absorber for joint loads. Viscosupplementation reduces the friction during the movements, assists the synovial fluids in creating more cushion, eliminates severe pain, and enhances the range of movements or motions of the joint. Apart from this, it restores the rheological properties of the synovial fluids, which produce mechanical, analgesic, anti-inflammatory, and chondroprotective effects. As a result, viscosupplementation is extensively utilized in the treatment of knee, hip, and hand osteoarthritis. Currently, it is mainly available in intermediate, low, and high molecular weights.

Viscosupplementation Market Trends:
The increasing prevalence of osteoporosis and osteoarthritis (OA) represents one of the key factors driving the market growth. In line with this, the shifting consumer inclination toward the minimally invasive non-surgical treatment options has facilitated the widespread adoption of viscosupplementation in the healthcare sector for corticosteroids and joint pain management. This, in turn, is acting as another major growth-inducing factor. This is further influenced by the growing consumer awareness regarding the multiple benefits of non-surgical treatments, including no hospitalization, fewer expenses, minimal complications, and better clinical outcomes and recovery rates. Additionally, the favorable government initiatives and significant investments by various pharmaceutical companies to launch novel drugs and different routes of administrations is supporting the market growth. Moreover, the emergence of ambulatory surgical centers (ACS) that offer intensive treatment to resolve surgical and non-surgical problems in various body parts, such as joints, ligaments, muscle, spine, and nerves, is favoring the market growth. Furthermore, the introduction of open-label single-injections with hydraulic acid is propelling the market growth. Apart from this, favorable health insurance reimbursement policies, the rising geriatric population, which is susceptible to chronic ailments, increasing number of individuals with chronic disability, collaborations and partnership among the key players, and continuous research and development (R&D) activities in the field of medical sciences are positively impacting the market growth.

Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each segment of the global viscosupplementation market, along with forecasts at the global, regional, and country level from 2024-2032. Our report has categorized the market based on type, age group, distribution channel, application and end use.

Type Insights:

Single Injection
Three Injection
Five Injection

The report has also provided a detailed breakup and analysis of viscosupplementation market based on the type. This includes single, three and five injection. According to the report, single injection represented the largest segment.

Age Group Insights:

Adults
Geriatrics

A detailed breakup and analysis of the viscosupplementation market based on the age group has also been provided in the report. This includes adults and geriatric. According to the report, geriatrics accounted for the largest market share.

Distribution Channel Insights:

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

The report has also provided a detailed breakup and analysis of viscosupplementation market based on the distribution channel. This includes hospital, retail and online pharmacies. According to the report, hospital pharmacies represented the largest segment.

Application Insights:

Knee Osteoarthritis
Hip Osteoarthritis
Hand Osteoarthritis
Others

A detailed breakup and analysis of the viscosupplementation market based on the application has also been provided in the report. This includes knee, hip and hand osteoarthritis. According to the report, knee osteoarthritis accounted for the largest market share.

End Use Insights:

Hospitals
Orthopedic Clinics
Others

The report has also provided a detailed breakup and analysis of viscosupplementation market based on the end use. This includes hospitals, orthopedic clinics, and others. According to the report, orthopedic clinics represented the largest segment.

Regional Insights:

North America
United States
Canada
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa

The report has also provided a comprehensive analysis of all the major regional markets that include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, the North America was the largest market for viscosupplementation. Some of the factors driving the North America viscosupplementation market included the rising geriatric population and the affordable health insurance reimbursement policies.

Competitive Landscape:
The report has also provided a comprehensive analysis of the competitive landscape in the global viscosupplementation market. Detailed profiles of all major companies have also been provided. Some of the companies covered include Anika Therapeutics Inc., Aptissen S.A., Bioventus LLC, Ferring Pharmaceuticals, Fidia Farmaceutici S.p.A., Johnson & Johnson, LG Chem Ltd., OrthogenRx Inc. (Avanos Medical Inc.), Sanofi S.A., Seikagaku Corporation, Virchow Biotech Private Limited, Zimmer Biomet, Zuventus HealthCare Ltd. (Emcure Pharmaceuticals Limited), etc.

Key Questions Answered in This Report:
How has the global viscosupplementation market performed so far and how will it perform in the coming years?
What are the drivers, restraints, and opportunities in the global viscosupplementation market?
What are the key regional markets?
Which countries represent the most attractive viscosupplementation markets?
What is the breakup of the market based on the type?
What is the breakup of the market based on the age group?
What is the breakup of the market based on the distribution channel?
What is the breakup of the market based on the application?
What is the breakup of the market based on the end use?
What is the competitive structure of the global viscosupplementation market?
Who are the key players/companies in the global viscosupplementation market?